Compare GRDN & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRDN | BCRX |
|---|---|---|
| Founded | 2004 | 1986 |
| Country | United States | United States |
| Employees | 3600 | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | N/A | 1995 |
| Metric | GRDN | BCRX |
|---|---|---|
| Price | $38.88 | $8.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $40.60 | $20.82 |
| AVG Volume (30 Days) | 355.8K | ★ 4.7M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 381.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,186,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.63 | $12.55 |
| P/E Ratio | $117.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.17 | $6.00 |
| 52 Week High | $41.36 | $11.31 |
| Indicator | GRDN | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.29 | 49.25 |
| Support Level | $31.74 | $8.36 |
| Resistance Level | $39.62 | $9.90 |
| Average True Range (ATR) | 1.43 | 0.41 |
| MACD | 0.26 | 0.01 |
| Stochastic Oscillator | 77.08 | 44.74 |
Guardian Pharmacy Services Inc is a pharmacy services company providing technology-enabled services to help residents of long-term health care facilities (LTCFs) adhere to appropriate drug regimens, reducing the cost of care and improving clinical outcomes. The Company provides high-touch clinical, drug dispensing, and administration services tailored to residents in assisted living facilities, behavioral health facilities, and group homes, while also serving residents in all types of LTCFs. It partners with residents, LTCFs, and health plan payors to help reduce errors in drug administration, manage drug regimens, and improve adherence. The Company derives its revenue mainly from the sale of pharmaceutical and medical products.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.